Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Targeting IKZF2 with molecular glue degraders for cancer immunotherapy. Local targets link to admitted publications; unresolved targets remain external evidence.
Improved survival with ipilimumab in patients with metastatic melanoma
10.1056/nejmoa1003466 · 2010 · External reference
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
10.1056/nejmoa1200690 · 2012 · External reference
Cancer immunotherapy using checkpoint blockade
10.1126/science.aar4060 · 2018 · External reference
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
10.1038/s41571-019-0175-7 · 2019 · External reference
Understanding the tumor immune microenvironment (TIME) for effective therapy
10.1038/s41591-018-0014-x · 2018 · External reference
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
10.1038/nm1093 · 2004 · External reference
Regulatory T cells and immune tolerance
10.1016/j.cell.2008.05.009 · 2008 · External reference
How regulatory T cells work
10.1038/nri2343 · 2008 · External reference
Regulatory T cells in cancer immunotherapy
10.1038/cr.2016.151 · 2017 · External reference
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
10.1016/j.ccell.2023.02.014 · 2023 · External reference
Helios, a T cell-restricted Ikaros family member that quantitatively associates with Ikaros at centromeric heterochromatin
10.1101/gad.12.6.782 · 1998 · External reference
Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells
10.4049/jimmunol.0904028 · 2010 · External reference
Helios expression is a marker of T cell activation and proliferation
10.1371/journal.pone.0024226 · 2011 · External reference
Helios+ and Helios- cells coexist within the natural FOXP3+ T regulatory cell subset in humans
10.4049/jimmunol.1201379 · 2013 · External reference
Stable inhibitory activity of regulatory T cells requires the transcription factor Helios
10.1126/science.aad0616 · 2015 · External reference
Instability of Helios-deficient Tregs is associated with conversion to a T-effector phenotype and enhanced antitumor immunity
10.1073/pnas.1604765113 · 2016 · External reference
Acute pharmacological degradation of Helios destabilizes regulatory T cells
10.1038/s41589-021-00802-w · 2021 · External reference
Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy
10.1016/j.chembiol.2023.02.005 · 2023 · External reference
Identification of germline monoallelic mutations in IKZF2 in patients with immune dysregulation
10.1182/bloodadvances.2021006367 · 2022 · External reference
Dominant negative variants in IKZF2 cause ICHAD syndrome, a new disorder characterised by immunodysregulation, craniofacial anomalies, hearing impairment, athelia and developmental delay
10.1136/jmg-2022-109127 · 2023 · External reference
A germline heterozygous dominant negative IKZF2 variant causing syndromic primary immune regulatory disorder and ICHAD
10.1007/s10875-025-01882-2 · 2025 · External reference
Targeted protein degradation: expanding the toolbox
10.1038/s41573-019-0047-y · 2019 · External reference
PROTAC targeted protein degraders: the past is prologue
10.1038/s41573-021-00371-6 · 2022 · External reference
Identification of a primary target of thalidomide teratogenicity
10.1126/science.1177319 · 2010 · External reference
Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs
10.1038/nsmb.2874 · 2014 · External reference
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells
10.1126/science.1244851 · 2014 · External reference
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
10.1126/science.aat0572 · 2018 · External reference
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
10.1038/nature14610 · 2015 · External reference
SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate
10.1038/s41589-018-0129-x · 2018 · External reference
Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy
10.1038/s41467-025-58431-z · 2025 · External reference
Design and development of IKZF2 and CK1α dual degraders
10.1021/acs.jmedchem.3c01736 · 2023 · External reference
AlphaFold Protein Structure Database in 2024: providing structure coverage for over 214 million protein sequences
10.1093/nar/gkad1011 · 2024 · External reference
10.1038/s41587-026-03237-7
10.1038/s41587-026-03237-7 · External reference
Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide
10.1038/nature13527 · 2014 · External reference
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins
10.1126/science.1244917 · 2014 · External reference
Rational discovery of molecular glue degraders via scalable chemical profiling
10.1038/s41589-020-0594-x · 2020 · External reference
HELIOS-expressing human CD8 T cells exhibit limited effector functions
10.3389/fimmu.2023.1308539 · 2023 · External reference
The transcription factor Helios restrains the anti-tumor capacity of CD8+ T cells
10.1016/j.celrep.2025.116680 · 2025 · External reference
Helios is a key transcriptional regulator of outer hair cell maturation
10.1038/s41586-018-0728-4 · 2018 · External reference
Loss-of-function mutation in IKZF2 leads to immunodeficiency with dysregulated germinal center reactions and reduction of MAIT cells
10.1126/sciimmunol.abe3454 · 2021 · External reference
Helios represses megakaryocyte priming in hematopoietic stem and progenitor cells
10.1084/jem.20202317 · 2021 · External reference
Suppression of Aiolos and Ikaros expression by lenalidomide reduces human ILC3-ILC1/NK cell transdifferentiation
10.1002/eji.201848075 · 2019 · External reference
Helios induces epigenetic silencing of Il2 gene expression in regulatory T cells
10.4049/jimmunol.1200792 · 2013 · External reference
Helios controls a limited subset of regulatory T cell functions
10.4049/jimmunol.1501704 · 2016 · External reference
Helios is a marker, not a driver, of human Treg stability
10.1002/eji.202149318 · 2022 · External reference
Comparative transcriptome analysis reveals distinct genetic modules associated with Helios expression in intratumoral regulatory T cells
10.1073/pnas.1720447115 · 2018 · External reference
Interferon-γ drives Treg fragility to promote anti-tumor immunity
10.1016/j.cell.2017.05.005 · 2017 · External reference
Single-cell gene expression reveals a landscape of regulatory T cell phenotypes shaped by the TCR
10.1038/s41590-018-0051-0 · 2018 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
10.1038/nature18611 · 2016 · External reference
Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
10.1038/nature16979 · 2016 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Redirecting the neo-substrate specificity of cereblon-targeting PROTACs to Helios
10.1021/acschembio.2c00439 · 2022 · External reference
Discovery of a novel series of iso-indolinone-based glutarimides as highly efficacious and selective IKZF2 molecular glue degraders
10.1021/acs.jmedchem.5c00668 · 2025 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Phase 1 DKY709A12101C study in patients with advanced solid tumors treated with DKY709, an IKZF2 degrader, alone or in combination with PDR001, a PD-1 inhibitor
10.1158/1538-7445.am2026-ct006 · 2026 · External reference
Overcoming CK1α liability in the discovery of a series of isoIndolinone Glutarimides as selective IKZF2 molecular glue degraders
10.1016/j.bmcl.2025.130263 · 2025 · External reference
The discovery of BMS-986449, a highly potent and selective degrader of the transcription factors Helios (IKZF2) and Eos (IKZF4) for the treatment of solid tumors
10.1158/1538-7445.am2025-nd05 · 2025 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Discovery of highly potent and selective IKZF2 degraders for cancer immunotherapy
10.1021/acs.jmedchem.6c00500 · 2026 · External reference
Discovery of novel potent triple IKZF1/2/3 degraders for the treatment of hematological cancers
10.1021/acs.jmedchem.5c01086 · 2025 · External reference
IKZF2 Degradation: it's time to take into account it when designing Cereblon-based PROTACs
10.1002/cbic.202400365 · 2024 · External reference
Anti-CTLA-4 generates greater memory response than anti-PD-1 via TCF-1
10.1073/pnas.2418985122 · 2025 · External reference
Leveraging structural and computational biology for molecular glue discovery
10.1021/acs.jmedchem.5c00076 · 2025 · External reference
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma
10.1182/blood.2020007081 · 2021 · External reference
Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
10.1182/blood-2018-05-852798 · 2018 · External reference
Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs
10.1073/pnas.1814446115 · 2018 · External reference
Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells
10.1172/jci153514 · 2022 · External reference
